Teva Pharmaceutical Industries (NYSE:TEVA) announced its earnings results on Thursday. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14, Morningstar.com reports. The company had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. Teva Pharmaceutical Industries’s quarterly revenue was down 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 earnings per share. Teva Pharmaceutical Industries updated its FY18 guidance to $2.25-2.50 EPS.

Shares of Teva Pharmaceutical Industries (TEVA) traded down $0.03 on Friday, hitting $18.61. The company’s stock had a trading volume of 21,758,602 shares, compared to its average volume of 20,338,289. The company has a market capitalization of $19,300.00, a price-to-earnings ratio of -3.17, a PEG ratio of 1.51 and a beta of 0.59. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94.

Institutional investors and hedge funds have recently modified their holdings of the business. Exane Derivatives bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at $571,000. Korea Investment CORP raised its stake in shares of Teva Pharmaceutical Industries by 14.3% in the third quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock valued at $4,308,000 after buying an additional 30,674 shares during the period. Private Capital Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 51.3% in the third quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock valued at $459,000 after buying an additional 8,850 shares during the period. Financial Counselors Inc. raised its stake in shares of Teva Pharmaceutical Industries by 28.8% in the third quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock valued at $3,188,000 after buying an additional 40,531 shares during the period. Finally, Lockheed Martin Investment Management Co. bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at $317,000. Hedge funds and other institutional investors own 51.99% of the company’s stock.

TEVA has been the topic of several analyst reports. Credit Suisse Group set a $20.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, January 22nd. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, November 27th. Royal Bank of Canada raised Teva Pharmaceutical Industries from an “underperform” rating to a “sector perform” rating and set a $18.00 target price on the stock in a research report on Friday. Finally, Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price target on the stock. in a report on Thursday, January 11th. Ten research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $21.15.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPS” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2018/02/08/teva-pharmaceutical-industries-teva-issues-quarterly-earnings-results.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.